Evaxion Appoints Dr. Helen Tayton-Martin as Chief Executive Officer
Evaxion A/S (NASDAQ: EVAX), a forward-thinking clinical-stage TechBio company renowned for its AI-Immunology™ powered vaccines, is thrilled to announce the appointment of Dr. Helen Tayton-Martin as its new Chief Executive Officer (CEO). Scheduled to officially start her role soon, Dr. Tayton-Martin is set to leverage her extensive expertise to propel the company's growth and innovation.
Dr. Tayton-Martin's Impressive Background in Biotechnology
Dr. Tayton-Martin comes to Evaxion with over 30 years of robust experience in the biotech sector, showcasing a proven ability to build companies, secure funding, manage mergers and acquisitions, and foster business development. Her career began in early research and has evolved through to pivotal roles in product approval specifically in cancer immunotherapy, establishing her as an exceptional fit for leading Evaxion into its next phase.
Leadership Experience with Adaptimmune
As a co-founder of the cancer-focused biotech firm Adaptimmune, Dr. Tayton-Martin excelled in roles including Chief Operating Officer and later Chief Business & Strategy Officer over a remarkable 17-year span. Here, she was responsible for significant transatlantic growth and orchestrated numerous strategic partnerships with notable entities like Astellas and GlaxoSmithKline, along with navigating the company through its IPO on Nasdaq.
Continued Expertise with Birgitte Rønø
Following Dr. Tayton-Martin's transition to CEO, Birgitte Rønø, who has served admirably as the interim CEO, will resume her position as Chief Scientific Officer. Her leadership during a crucial phase for Evaxion has been invaluable, ensuring continuity in the company's research and development efforts.
Recognizing Contributions and Future Directions
Marianne Søgaard, Chairman of the Board at Evaxion, expressed confidence in Dr. Tayton-Martin's capabilities, stating, "Dr. Tayton-Martin's leadership and her understanding of our business will help realize Evaxion’s strategic initiatives. We are excited about her joining us at such an important time."
A New Advisor Joins the Board
With Dr. Tayton-Martin stepping down from the Board upon her appointment, Jens Bitsch-Norhave, a seasoned life science executive, will join as an observer and advisor. He aims for election to the Board at the upcoming Annual General Meeting, further strengthening Evaxion’s governance.
The Impact of Jens Bitsch-Norhave
Jens brings with him over 25 years of experience within the biotech and pharmaceutical industries, focusing on corporate strategy, business development, and global expansions. Currently, he serves as Corporate Vice President at Hengrui Pharmaceuticals and is well equipped to advise Evaxion's Board in navigating future challenges and opportunities.
Evaxion: Pioneering Innovations in TechBio
Evaxion stands at the forefront of the biotech field, utilizing its innovative AI-Immunology™ platform to develop cutting-edge immunotherapies aimed at cancer, bacterial infections, and viral diseases. The company's commitment to harnessing artificial intelligence represents a transformative approach to healthcare, paving the way for targeted and novel treatment options.
Looking Ahead with Excitement
Dr. Tayton-Martin has expressed enthusiasm about leading Evaxion during a transformative phase, particularly highlighting the recent successes such as the out-licensing of EVX-B3 to MSD and the groundbreaking data presented for EVX-01. As she embarks on this new journey, Dr. Tayton-Martin is keen to collaborate with the dedicated team at Evaxion to unlock the full potential of their scientific innovation.
Frequently Asked Questions
Who is Dr. Helen Tayton-Martin?
Dr. Helen Tayton-Martin is the newly appointed CEO of Evaxion, with over 30 years in biotech, previously co-founding and leading Adaptimmune.
What is Evaxion’s focus?
Evaxion focuses on providing AI-powered immunotherapies for cancer and infectious diseases, harnessing proprietary AI technologies to develop innovative treatments.
What role will Birgitte Rønø play?
Birgitte Rønø will return to her position as Chief Scientific Officer after serving as the interim CEO, continuing her influential work in research and development.
What does Jens Bitsch-Norhave bring to the Board?
With decades of experience in the biotech field, Jens Bitsch-Norhave will provide strategic guidance as an advisor, enhancing Evaxion’s Board of Directors.
What is the significance of the AI-Immunology™ platform?
AI-Immunology™ enables Evaxion to analyze complex immune responses, leading to the development of personalized vaccines and therapies that address unmet medical needs.
